Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $124,560 | 2 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $124,560 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2017 | $124,560 | 2 | E.R. Squibb & Sons, L.L.C. ($124,560) |
All Payment Transactions
2 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/02/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $58,320.00 | Research |
| Study: A Randomized Multi center Phase III Study of Nivolumab Versus Sorafenib as First Line Treatment in Patients With Advanced Hepatocellular Carcinoma CheckMate 459 CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459 • Category: Oncology | ||||||
| 01/19/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $66,240.00 | Research |
| Study: A Phase 1 2 Dose escalation Open label Non comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis and a Randomized Open label Study of Nivolumab vs S • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1 2 Dose escalation Open label Non comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis and a Randomized Open label Study of Nivolumab vs S | E.R. Squibb & Sons, L.L.C. | $66,240 | 1 |
| A Randomized Multi center Phase III Study of Nivolumab Versus Sorafenib as First Line Treatment in Patients With Advanced Hepatocellular Carcinoma CheckMate 459 CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459 | E.R. Squibb & Sons, L.L.C. | $58,320 | 1 |
About Dr. Dania Cioni, MD
Dr. Dania Cioni, MD is a Diagnostic Radiology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2015. The National Provider Identifier (NPI) number assigned to this provider is 1205209905.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dania Cioni, MD has received a total of $124,560 in payments from pharmaceutical and medical device companies, with $124,560 received in 2017. These payments were reported across 2 transactions from 1 company. The most common payment nature is "" ($124,560).
Practice Information
- Specialty Diagnostic Radiology
- Location Miami, FL
- Active Since 11/04/2015
- Last Updated 11/04/2015
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1205209905
Products in Payments
- OPDIVO (Biological) $124,560
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Miami
Mr. James Benenati, Md, MD
Diagnostic Radiology — Payments: $6.5M
Mr. George Oliveira, M.d, M.D
Diagnostic Radiology — Payments: $1.4M
Guilherme Dabus, Md, MD
Diagnostic Radiology — Payments: $509,504
Mr. Barry Katzen, Md, MD
Diagnostic Radiology — Payments: $445,306
Dr. Italo Linfante, M.d, M.D
Diagnostic Radiology — Payments: $284,276
Riccardo Lencioni, Md, MD
Diagnostic Radiology — Payments: $225,564